Key result
Central venous access device insertion in patients with type I persistent left superior vena cava was safe, with normal function and no obvious complications observed over 1537 days of retention.
Why the study?
Whether central venous access devices can be placed and used in patients with persistent left superior vena cava was controversial.
Is central venous access device placement safe and feasible in cancer patients with persistent left superior vena cava?
Observational (n=6)
No
Is central venous access device placement safe and feasible in cancer patients with persistent left superior vena cava?
CVAD insertion in patients with type I PLSVC is safe and feasible when guided by IC-EKG showing negative P-waves in lead II.
May support IC-EKG-guided CVAD placement in PLSVC; hypothesis-generating and requires prospective validation before practice change.
Persistent left superior vena cava (PLSVC) is a rare congenital anomaly. PLSVC can be associated with clinically significant atrial septal defect (ASD) or ventricular septal defect (VSD). It is usually asymptomatic and accidentally detected during invasive procedures or imaging examinations. However, whether central venous access device (CVAD) can be placed and used in patients with PLSVC is controversial. A total of six patients were diagnosed with PLSVC and confirmed by chest CT among 3391 cancer patients who underwent CVAD placement via intracavitary electrocardiogram (IC-EKG) at the Venous Access Center (VAC) from May 2019 to December 2020. The CVADs (peripherally inserted central catheter in four patients and Ports in two patients) of these six patients were left in PLSVC. We analyzed changes in the P-wave in the IC-EKG during CVAD placement and the characteristics of the body surface electrocardiogram in these patients and discussed the catheter tip position in PLSVC. All six patients showed negative P-waves in lead II via IC-EKG from the beginning of catheterization: four patients showed negative P-waves and two showed biphasic P-waves in the body surface electrocardiogram (lead III) before catheterization. CVAD function was normal and no obvious complications were observed during the treatment of these patients. The total retention time of CVADs was 1537 days. For patients with a negative P-wave in lead II via IC-EKG during catheterization, especially in those with a negative or biphasic P-wave in lead III of the body surface electrocardiogram, PLSVC should be considered. CVAD insertion in patients with type I PLSVC is safe under certain conditions, with the proper tip position in the middle to lower part of PLSVC.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted an observational in Cancer patients with persistent left superior vena cava (PLSVC) (n=6). Central venous access device (CVAD) placement was evaluated on CVAD function and complications. Central venous access device insertion in patients with type I persistent left superior vena cava was safe, with normal function and no obvious complications observed over 1537 days of retention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: